[ Price : $8.95]
Bristol Myers Squibb says its Breyanzi showed positive results in a Phase 1/2 trial in patients with relapsed or refractory chroni...[ Price : $8.95]
AstraZeneca says the Phase 3 DUO-E trial showed significant progression-free survival of endometrial cancer with its Imfinzi plus ...[ Price : $8.95]
FDA releases the form FDA-483 with three observations from an inspection at the UCB Pharma drug manufacturing facility in Braine-l...[ Price : $8.95]
FDA requires updates to Boxed Warnings for prescription stimulants indicated to treat ADHD and other conditions.[ Price : $8.95]
Three stakeholders comment and make recommendations following an FDA listening session on methods and approaches for capturing pos...[ Price : $8.95]
Federal Register notice: FDA determines that a Fresenius Kabi NDA for heparin sodium injection was not withdrawn for reasons of sa...[ Price : $8.95]
Germany-based Berlin Heart recalls its Excor Pediatric Ventricular Assist Device Blood Pumps due to the potential for therapy disr...[ Price : $8.95]
FDA accepts for priority review a Takeda and Hutchmed NDA for fruquintinib, indicated for treating adult patients with previously ...